In this systematic review and network meta-analysis, we comprehensively summarize the comparative efficacy and safety of PI3K inhibitor (alpelisib, buparlisib, taselisib, and pictilisib) treatments for patients with any stage and any receptor type of BC. The gene discussed is PIK3CA; the disease is breast cancer.